New hope for kids with tough cancers: boosting the Body's own defenses
NCT ID NCT07375563
Summary
This study is testing a combination treatment for children with high-risk neuroblastoma that has not responded to or has come back after initial therapy. It combines standard chemotherapy and immunotherapy drugs with an infusion of the patient's own specially grown immune cells, called NK cells. The goal is to better control the cancer, improve survival, and enhance quality of life for these children.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITINGMoscow, 117198, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.